Serotonin syndrome risks when combining SSRI/SNRI drugs and triptans: Is the FDA's alert warranted?

Annals of Pharmacotherapy

Volumn 42, Issue 11, 2008, Pages 1692-1696

  Wenzel, Richard G ^a,d   Tepper, Stewart ^b   Korab, William E ^c   Freitag, Fredrick ^d  

^a SAINT JOSEPH HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d DIAMOND HEADACHE CLINIC   (United States)

Author keywords

Selective serotonin reuptake inhibitor; Selective serotonin norepinephrine reuptake inhibitor; Serotonin syndrome; Triptans

Indexed keywords

DIPHENHYDRAMINE; ELETRIPTAN; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; MONOAMINE OXIDASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE;

CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION DISSEMINATION; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEROTONIN SYNDROME; SYMPTOM;

ADRENERGIC UPTAKE INHIBITORS; ADVERSE DRUG REACTION REPORTING SYSTEMS; HUMANS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 55949090829     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L260     Document Type: Note

References (32)

1. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47:355-63.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder. JAMA 2003;289:3095-105.
3. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KMA. Comorbidity of migraine and depression. Neurology 2003;60:1308-12.
4. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KMA. Headache and major depression. Neurology 2000;54:308-13.
5. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 2000;132:738-42.
6. Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache. Neurology 2000;55:754-63.
7. Goadsby PJ, Lipton RB, Ferrari MD. Drug therapy: migraine - current understanding and treatment. N Engl J Med 2002;346:257-70.
8. Data on file. Sumatriptan period safety update report, 10 April 2005 to 30 September 2005. Document No. GM/2005/00431/00. Research Triangle Park, NC: GlaxoSmithKline.
9. Burt CW, McCaig LF, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2005. Adv Data 2007;388:1-16.
10. Gardner DM, Lynd LD. Sumatriptan contraindications and the serotonin syndrome. Ann Pharmacother 1998;32:33-8. DOI 10.1345/aph.17204
11. Food and Drug Administration. Potentially life-threatening serotonin syndrome with combined use of SSRIs or SNRIs and triptan medications. www.fda.gov/cder/drug/InfoSheets/HCP/triptansHCP.htm (accessed 2007 Nov 7).
12. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112-20.
13. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;48:705-13.
14. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-23.
15. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999;49:871-4.
16. Mills KC. Serotonin syndrome. Crit Care Clin 1997;13:763-83.
17. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996;30:527-33.
18. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics, and serotonin toxicity. Br J Anaesth 2005;95:434-41.
19. Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 2006;59:1046-51.
20. McDaniel WW. Serotonin syndrome: early management with cyproheptadine. Ann Pharmacother 2001;35:870-3. DOI 10.1345/aph.10203
21. Shapiro RE, Tepper S. The serotonin syndrome, triptans, and the potential for drug-drug interactions. Headache 2007;47:266-9.
22. Bonetto N, Santelli L, Battistin L, Cagnin A. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine, and hypericum. Cephalalgia 2007;27:1421-3.
23. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 1996;16:323-7.
24. Joffe RT, Kokolov STH. Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr Scand 1997;95:551-2.
25. Putnam GP, O'Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW. Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia 1999;19:668-75.
26. Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S. Coprescriptions of triptans with potential interacting medications: a cohort study involving 240268 patients. Headache 2003;43:44-8.
27. Sclar DA, Robison LM, Skaer TL. Concomitant triptan and SSRI or SNRI use; a risk for serotonin syndrome. Headache 2008;48:126-9.
28. Evans RW. The FDA alert on serotonin syndrome with combined use of SSRI or SNRI and triptans: an analysis of 29 case reports. Medscape General Medicine 2007;9(3):48. www.medscape.com/viewarticle/561741 (accessed 2007 Dec 9).
29. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med 2003;96:635-42.
30. Soldin OF, Tonning JM. Serotonin syndrome associated with triptan monotherapy (letter). N Engl J Med 2008;358:2185-6.
31. Gillman K. Serotonin toxicity (letter). Headache 2008;48:640-1.
32. Gillman PK. Extracting value from case reports: lessons from serotonin toxicity (serotonin syndrome). Anaesthesia 2006;61:419-22.